|
|
||||||||
Cardiovascular Institute, University of Pittsburgh Health System, Pittsburgh, Pennsylvania 15213
| |
ABSTRACT |
|---|
|
|
|---|
Transgenic (TG) TNF1.6
mice, which cardiac specifically overexpress tumor necrosis factor-
(TNF-
), exhibit heart failure (HF) and increased mortality, which is
markedly higher in young (<20 wk) males (TG-M) than females (TG-F). HF
in this model may be partly caused by remodeling of the extracellular
matrix and/or structure/function alterations at the single myocyte
level. We studied left ventricular (LV) structure and function using
echocardiography and LV myocyte morphometry, contractile function, and
intracellular Ca2+ (Ca
-myosin heavy chain and atrial natriuretic factor versus TG-F mice,
reduced FS relative to both WT and TG-F mice, and minimal response to
Iso. TG-F and TG-M myocytes were similarly elongated (by
20%). The
amplitude of Ca




induces myocyte hypertrophy
and gender-dependent alterations in Ca
transgenic mice; gender; heart failure; calcium; echocardiography
| |
INTRODUCTION |
|---|
|
|
|---|
TUMOR NECROSIS
FACTOR-
(TNF-
) is a pleiotropic peptide that is
elevated in the sera and myocardium of patients with heart failure
(HF). Its importance in the pathophysiology of left ventricular (LV)
dysfunction was first recognized in studies demonstrating acute
negative inotropic effects on single cardiac myocytes and isolated
heart preparations (1, 14, 16, 26, 61). Furthermore, rats
subjected to prolonged (15 day) intraperitoneal infusion of TNF-
developed reversible LV dilatation and dysfunction associated with a
reduced contractility of isolated LV myocytes (5). To further elucidate the role of TNF-
in the development of HF, we
created transgenic (TG) mice with cardiac-restricted overexpression of
TNF-
(TNF1.6 mice) (29). The TNF1.6 mice
(29) and similar TNF-
overexpressor mice
(7) exhibited a HF phenotype with ventricular hypertrophy,
fibrosis, extracellular matrix remodeling, dilatation, diminished LV
function, loss of
-adrenergic responsiveness, activation of fetal
gene programs, and premature death. The TNF1.6 mice showed a striking
gender-dependent difference in the severity of LV dysfunction and
mortality between young (<20 wk of age) male (TG-M) and female (TG-F)
TNF1.6 mice, despite identical levels of TNF-
expression
(24).
Changes in LV structure and function in HF result from several
processes, including fibrotic remodeling of the extracellular matrix,
realignment (slippage) of myocytes within the LV wall, and/or
alterations in the structure and contractility of individual LV
myocytes (6, 22, 38). Both altered intracellular
Ca2+ (Ca

in vitro.
However, it is unclear whether the diminished ventricular function
effected by chronic exposure to TNF-
in vivo is attributable to the
intrinsic changes at the single myocyte level or to extracellular
matrix remodeling and changes in LV geometry. The present study was
designed to determine whether and to what extent alterations in LV
structure and function in mice overexpressing TNF-
are related to
changes in the morphometry, Ca
| |
METHODS |
|---|
|
|
|---|
Animals. Twelve-week-old TG mice (TNF1.6) and their wild-type (WT) littermates (29) were utilized under protocols approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh. Twelve-week-old mice were utilized in these studies because gender-dependent differences were most marked at that age (24, 32).
Echocardiography. Echocardiographic studies were performed on 12-wk-old TNF1.6 mice and their WT littermates with an ultrasonograph system (Sequoia 512, Acuson), using methods described in detail previously (24, 32).
Myocyte isolation. LV myocytes were isolated using the method described by Xu et al. (59). Briefly, hearts were perfused by the Langendorff method with HEPES-buffered Earle's balanced salt solution (GIBCO-BRL) supplemented with 6 mM glucose, amino acids, and vitamins (buffer A) and then with buffer A containing 0.8 mg/ml collagenase B (Boehringer-Mannheim) and 10 µM CaCl2 at 35°C. The enzyme solution was filtered (2-µm pores) and recirculated through the heart until the flow rate doubled (12-20 min); the LV was then removed and minced in collagenase-containing buffer A. Thereafter, the tissue pieces were transferred to fresh (enzyme free) buffer A supplemented with 1.25 mg/ml taurine, 5 mg/ml BSA (Sigma), and 150 µM CaCl2 and mechanically dissociated by gentle trituration. The resulting suspension was filtered, and isolated cells were obtained by sedimentation. The myocytes were kept in buffer B containing 500 µM CaCl2 until used, usually within 5-7 h.
Measurement of cell size and shortening.
The morphological and mechanical properties of the myocytes and
Ca
Measurement of Ca



Analysis of transcript levels.
For measurements of mRNA levels of
-myosin heavy chain (MHC),
-MHC, atrial natriuretic factor (ANF), cardiac sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) 2, and phospholamban (PLB),
hearts were removed from euthanized mice and flash frozen. RNA
isolation, Northern blot hybridizations, preparation of cDNA and
oligonucleotide probes, and quantitative analysis of hybridized filters
were performed as previously reported (28). Hybridization
signals were normalized to that of the 18S probe to correct for
differences in RNA mass and efficiency of transfer. For evaluation with
respect to both genotype and gender, the data were normalized to the
mean of the male and female WT samples combined, arbitrarily set at
100%.
Analysis of protein expression. For measurements of protein expression of SERCA 2 and PLB using Western blots, frozen hearts were homogenized [50 mM KHPO4 (pH 7.0), 0.3 M sucrose, 10 mM NaF, 1 mM EDTA, and 0.5 M dithiothreitol] and briefly centrifuged to remove gross debris. Protein levels were determined (Bio-Rad) using bovine IgG as a standard. Proteins were subjected to gel electrophoresis, transferred to nitrocellulose membranes, interacted with antibodies, washed, developed by chemiluminescence, and quantified as previously described (41). Antibodies included anti-PLB monoclonal antibody (1 µg/ml, Upstate Biotechnology) or rabbit polyclonal anti-SERCA antibody (5 µg/ml, Zymed). Filters were stripped and reinteracted with anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH; diluted 1:1,000, Research Diagnostics) with the resultant GAPDH signal serving to normalize the protein mass loaded and transferred. These results, representing an average of four experiments, were in turn normalized to the mean of the male and female WT samples combined, arbitrarily set at 100%.
Statistics. Results are presented as means ± SE; n indicates the number of mice. For experiments in isolated myocytes, 4-8 and 11-15 cells from individual hearts were used for functional and morphometric assessments, respectively, and each heart was treated as a single n. Statistical significance of differences was determined using ANOVA with a post hoc Student-Newman-Keuls test in morphometric and functional measurements and using ANOVA and Tukey's post hoc test in molecular studies. Values of P < 0.05 were considered statistically significant.
| |
RESULTS |
|---|
|
|
|---|
LV structure and function.
At 12 wk of age, male and female WT mice were not different with
respect to the parameters assessed using echocardiography and
gravimetric measurements in explanted hearts (Table
1). Compared with WT mice, TG-F mice
showed a significant increase in LV weight and the LV weight-to-body
weight ratio. Cardiac systolic performance, indexed by fractional
shortening (FS), was only slightly reduced in TG-F versus WT mice at
baseline, whereas the Iso-dependent increase in FS was significantly
smaller in TG-F mice (Table 1). In contrast, TG-M littermates exhibited
a significantly larger increase in the LV weight-to-body weight
relative relative to TG-F mice and LV dilation relative to both WT and
TG-F mice. Also, baseline LV systolic dimension and FS were
significantly reduced in TG-M mice compared with both WT and TG-F mice
and failed to appreciably increase after Iso challenge. Heart rate,
measured under anesthesia, and body weight, assessed gravimetrically,
were similar in all compared groups (Table 1). The present
echocardiographic results support those reported previously in TNF1.6
mice (23, 31).
|
Gene expression at transcript levels.
Northern blot analysis showed that relative to WT hearts, transcripts
encoding
-MHC, SERCA 2, and PLB were significantly reduced, whereas
transcripts encoding
-MHC and ANF were significantly increased, in
TG hearts (Fig. 1, A and
B). Additional patterns of
gene expression emerged upon categorization of the hearts by both
genotype and gender (Fig. 1, C-G). Specifically,
whereas both TG-M and TG-F hearts showed significantly elevated
expression of ANF and
-MHC transcripts compared with WT littermates,
a relative increase in these two transcript was approximately twofold
larger in TG-M versus TG-F hearts (Fig. 1, C and
D). Message levels of
-MHC, SERCA 2, and PLB were
significantly reduced in TG versus WT hearts when assessed with respect
to both genotype and gender (Fig. 1, E-G). Figure 1,
E-G, also shows higher message levels of
-MHC, SERCA
2, and PLB in male versus female WT hearts and a lack of significant
gender differences of these transcripts in TG hearts.
|
Protein expression of SERCA 2 and PLB.
An impaired Ca2+ handling in TG myocytes (see Figs. 3 and 4
and Table 2) may be consequent to an altered protein expression and/or
function of SERCA-2 or PLB (6, 22). To directly address this issue, we examined the protein expression of SERCA 2 and PLB
proteins using Western blotting. Protein levels of SERCA 2 or PLB were
not different in TG versus WT hearts (Fig.
2) or in male versus female mice in both
groups (data not shown).
|
|
Structural and functional properties of isolated LV myocytes.
At 12 wk of age, there were no appreciable differences between myocytes
isolated from WT male and female mice, and both groups were combined
and denoted as WT mice. Figures 3 and
4A show representative examples of basal contractile function and Ca
20%, P < 0.001), whereas the cell width was
not different among the compared groups. The length-to-width ratio was
the same in TG-F and TG-M myocytes and was significantly increased
relative to WT myocytes (Table 2). During steady-state stimulation at 0.5 Hz, Ca





dCa




|
|
Effect of
-adrenergic stimulation on
Ca


5-7%, not different from control (P = not
significant). Potentiation of the amplitude of the
Ca

dCa


dCa
|
| |
DISCUSSION |
|---|
|
|
|---|
Our findings in single myocytes, combined with the
assessments of changes in the structure and function of age-matched
hearts in vivo, provide several new observations relevant to cardiac pathophysiology consequent to overexpression of TNF-
. First, we
found that that LV myocytes isolated from TNF1.6 male mice display
significant abnormalities in Ca
-adrenergic response, whereas myocytes
isolated from TNF1.6 females differ from WT myocytes only in the slower
kinetics of the Ca
-MHC. Finally, we find that an impaired
Ca
Molecular remodeling in TNF1.6 mice.
Reactivation of the embryonic gene program is a characteristic feature
of cardiac hypertrophy and failure (8, 25). Consistently, transcripts of ANF and
-MHC were significantly increased in TG versus WT hearts (Fig. 2, A-D). Interestingly, whereas
male and female TG hearts displayed a similar extent of cardiac
hypertrophy (indexed by the LV mass-to-body weight ratio; Table 1) and
cellular hypertrophy (Table 2), the increase in ANF and
-MHC mRNA
was approximately twofold larger in TG males than in females (Fig. 1,
C and D). This difference may reflect, in
part, increased transmural tension/myocyte stretch, a potent modulator
of gene expression in cardiac myocytes (25), consequent to
a significant dilatation of TG male hearts (Table 1). The pattern of
changes in
-MHC transcripts (Fig. 1, A, B, and
E) was opposite to that of
-MHC transcripts, consistent
with a partial replacement of
-MHC with
-MHC in hypertrophied and
failing hearts (35, 47). Compared with WT hearts,
transcripts of SERCA 2 and PLB were significantly reduced in TG hearts
(Fig. 1, A, B, F, and G).
These findings are compatible with reports in human failing hearts
(33, 42) and experimental hypertrophy (9, 46,
56). We also observed relatively higher message levels of
-MHC, SERCA 2, and PLB in WT males versus females (Fig. 1,
E-G). However, these differences were not reflected in
the function of WT hearts or isolated myocytes (Tables 1 and 2) or
protein expression of SERCA 2 or PLB.
Structural remodeling in TNF1.6 mice.
Structural remodeling of the heart (i.e., changes in mass and/or
geometry) is consequent to several processes, including fibrotic remodeling of the extracellular matrix, structural alterations of
individual cardiac myocytes, their displacement within the cardiac
wall, and/or alternations in the abundance of nonmyocyte cardiac cells
(2, 6). Morphometry of single LV myocytes isolated from
TNF1.6 mice showed that compared with WT myocytes, the length of TG-F
and TG-M myocytes was similarly, significantly increased (by
20%),
whereas the cell width was virtually the same in all experimental
groups (Table 2). These observations are consistent with morphometric
changes in ventricular myocytes isolated from human failing hearts
(15) and with gravimetric measurements in TNF1.6 hearts
(Table 1). Hypertrophy of the LV chamber and single myocytes (Table 1
and 2) may arise, in part, from a direct hypertrophic effect of TNF-
on cardiac myocytes. Such an effect has been suggested based on a
substantial increase in protein synthesis (including sarcomeric
proteins) in transiently cultured adult cardiac myocytes stimulated
with TNF-
(61). Also, a moderate (
11%) increase in
the myocyte cross-sectional area and a
20% increase in the cell
volume has been previously shown to occur after a 15-day TNF-
infusion (intraperitoneally) in rats (5). Interestingly,
the degree of cardiac and cellular hypertrophy was nearly identical in
TG-F and TG-M mice, despite marked differences in the contractile
function of hearts in situ and isolated LV myocytes (Table 1 and 2).
These findings suggest that structural remodeling of LV myocytes may
precede the myocyte (or cardiac) contractile dysfunction. Hypertrophy
consequent primarily to increased length, as observed in 12-wk-old
TNF1.6 mice, is thought to lead to an earlier LV dilatation and
contractile dysfunction compared with transverse myocyte growth
(6, 50). This type of myocyte remodeling is not unique to
cardiac hypertrophy and/or failure consequent to overexpression of
TNF-
. For example, recent studies in a hypertensive rat model of HF
have shown that LV myocytes exhibit a maladaptive lengthening long
before LV pump failure and are apparently devoid of an adaptive ability
to normalize wall stress through transverse growth (50).
More importantly, the present results show that TG overexpression of
TNF-
affects myocyte hypertrophy and function through different
pathways because, in contrast to functional differences, the extent of
hypertrophy in TNF1.6 mice was not gender dependent (Tables 1 and 2).
22% larger in TG-M
than TG-F mice, and a similar trend observed in WT mice nearly achieved
statistical significance (Table 1). Thus, in the absence of gender
differences in myocyte size in WT and TG mice, the larger LV mass in
TG-M mice might simply be a consequence of the larger number of
myocytes in male hearts. Other potential factors include a more
extensive inflammatory infiltration and/or more extensive fibrotic
remodeling in TG males. With respect to the latter, it is of note that
myocyte apoptosis/necrosis is relatively small in young TG
hearts (29) and, therefore, "replacement" type of
fibrosis may be expected to be low in these hearts. In contrast to TG
males, elongation of LV myocytes in TG-F mice was not associated with
an increase in LV diastolic dimension measured by echocardiography
(Table 1). A possible explanation for this discrepancy would be that
the relationship between the slack length of isolated myocytes and LV
diastolic dimension of hearts in situ is different in TG versus WT
mice, due to differences in other factors that are thought to modulate LV diastolic dimension. These include
-adrenergic tone, coronary blood flow, myocyte relaxation in vivo, diastolic filling pressure, LV
compliance, and/or regional asynchrony of LV relaxation
(4). Nevertheless, we cannot rule out the possibility that
a subpopulation of myocytes exhibiting extreme structural remodeling
was more prone to damage during the enzymatic dispersion and,
therefore, contributed to changes of the LV diastolic dimension in situ
but was underrepresented in the morphometric assessments in isolated myocytes.
Functional remodeling in TNF1.6 mice.
One of the important findings of the present study is that in both TG-M
and TG-F hearts, changes in the functional properties of single
myocytes closely corresponded to functional changes in age-matched
hearts in situ. Thus these results suggest that cardiac function in
young TNF1.6 mice is determined, at least in part, at the myocyte
level. Specifically, compared with WT littermates, 12-wk-old TG-F mice
displayed a near normal basal cardiac function, as determined by
echocardiographic assessments of basal FS, but a blunted increase of FS
in response to Iso (Table 1). In contrast, age-matched TNF1.6 males
displayed cardiac function consistent with HF, as evidenced by a
significantly reduced basal FS and virtually no increase of FS in
response to Iso (Table 1). Compared with WT myocytes, TG-M myocytes
exhibited a significant reduction in the amplitude and kinetics of
Ca

dCa

dCa











Gender differences.
Consistent with the present findings, we recently reported a more
severe cardiac dysfunction and markedly higher mortality in young (<20
wk) TNF1.6 males versus females (23, 24). Whereas other
laboratories have also generated mice that display HF consequent to
cardiac-specific overexpression of TNF (7, 55), they did not report the sex of mice employed or whether gender differences were
actually considered. Thus it is not clear whether the gender differences we observed (Refs. 23 and 24 and
the present results) are unique to this line of TNF-
overexpressor
mice. Interestingly, a more rapid onset and/or a greater severity of
cardiac dysfunction in male versus female hearts have been recently
reported in other transgenic models of HF (18, 49) and in
a rat model of cardiac hypertrophy (12, 56). Our previous
study (24) suggested that gender differences in TNF1.6
mice may be related, in part, to the higher expression of TNF receptor
transcripts and higher production of ceramide, a TNF-
-activated
second messenger, in male hearts. Other recent studies have indicated
that alterations in cardiac telomerase activity (30) or
replicative capacity of cardiac fibroblasts in response to hypoxia
(17) may also contribute to the more severe cardiac
dysfunction in males versus females. There is also strong, although
indirect, evidence that sex hormones may affect the translation and/or
function of proteins implicated in cardiac structure, contractile
function, and Ca2+ homeostasis (37, 53, 56).
Nonetheless, gender differences in the context of HF remain
incompletely understood. Thus the gender differences in structural and
functional remodeling of hearts and myocytes characterized in the
TNF1.6 mouse line suggests its potential use as a model to elucidate
specific mechanisms underlying gender-dependent differences in the
onset and severity of HF.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: A. M. Feldman, Jefferson Medical College, 10250 Walnut St., Rm. 822, Philadelphia, PA 19107 (E-mail: arthur.feldman{at}mail.tju.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
First published December 5, 2002;10.1152/ajpheart.0718.2001
Received 13 August 2001; accepted in final form 5 November 2002.
| |
REFERENCES |
|---|
|
|
|---|
1.
Alloatti, G,
Penna C,
De Martino A,
Montrucchio G,
and
Camussi G.
Role of nitric oxide and platelet-activating factor in cardiac alterations induced by tumor necrosis factor-
in the guinea-pig papillary muscle.
Cardiovasc Res
41:
611-619,
1999
2.
Baig, K,
Mahon N,
McKenna WJ,
Caforio ALP,
Bonow R,
Francis GS,
and
Gheorghiade M.
The pathophysiology of advanced heart failure.
Am Heart J
35:
S216-S230,
1998.
3.
Beuckelmann, DJ,
Nabauer M,
and
Erdmann E.
Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure.
Circulation
85:
1046-1055,
1992.
4.
Bonow, RO.
Left ventricular filling in ischemic and hypertrophic heart disease.
In: Diastolic Relaxation of the Heart, edited by Grossman W,
and Lorell BH.. Boston, MA: Nijhoff, 1988.
5.
Bozkurt, B,
Kribbs SB,
Clubb FJ,
Michael LH,
Didenko VV,
Hornsby PJ,
Seta Y,
Oral H,
Spinale FG,
and
Mann DL.
Pathophysiologically relevant concentrations of tumor necrosis factor-
promote progressive left ventricular dysfunction and remodeling in rats.
Circulation
97:
1382-1391,
1998.
6.
Braunwald, E,
and
Bristow MR.
Congestive heart failure: fifty years of progress.
Circulation
102, Suppl 4:
IV14-IV23,
2000.
7.
Bryant, D,
Becker L,
Richardson J,
Shelton J,
Franco F,
Peshock R,
Thompson M,
and
Giroir B.
Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha.
Circulation
97:
1375-1381,
1998.
8.
Chien, KR,
Zhu H,
Knowlton KU,
Miller-Hance W,
van Bilsen M,
O'Brien TX,
and
Evans SM.
Transcriptional regulation during cardiac growth and development.
Annu Rev Physiol
55:
77-96,
1993.
9.
De la Bastie, D,
Levitsky D,
Rappaport L,
Mercadier JJ,
Marotte F,
Wisnewsky C,
Brovkovich V,
Schwartz K,
and
Lompre AM.
Function of the sarcoplasmic reticulum and expression of its Ca2+-ATPase gene in pressure overload-induced cardiac hypertrophy in the rat.
Circ Res
66:
554-564,
1990
10.
Dipla, K,
Mattiello JA,
Jeevanandam V,
Houser SR,
and
Margulies KB.
Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure.
Circulation
97:
2316-2322,
1998.
11.
Dollery, CM,
McEwan JR,
and
Henney AM.
Matrix metalloproteinases and cardiovascular disease.
Circ Res
77:
863-868,
1995
12.
Douglas, PS,
Katz SE,
Weinberg EO,
Chen M,
Bishop SP,
and
Lorell BH.
Hypertrophic remodeling: gender differences in the early response to left ventricular pressure overload.
J Am Coll Cardiol
32:
1118-1125,
1998
13.
Feldman, AM,
Weinberg EO,
Ray PE,
and
Lorell BH.
Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding.
Circ Res
73:
184-192,
1993[Abstract].
14.
Finkel, MS,
Oddis CV,
Jacob TD,
Watkins SC,
Hattler BG,
and
Simmons RL.
Negative inotropic effects of cytokines on the heart mediated by nitric oxide.
Science
257:
387-389,
1992
15.
Gerdes, AM,
Kellerman SE,
Moore JA,
Muffly KE,
Clark LC,
Reaves PY,
Malec KB,
McKeown PP,
and
Schocken DD.
Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy.
Circulation
86:
426-430,
1992.
16.
Goldhaber, JI,
Kim KH,
Natterson PD,
Lawrence T,
Yang P,
and
Weiss JN.
Effects of TNF-
on [Ca2+]i and contractility in isolated adult rabbit ventricular myocytes.
Am J Physiol Heart Circ Physiol
271:
H1449-H1455,
1996
17.
Griffin, M,
Lee HW,
Zhao L,
and
Eghbali-Webb M.
Gender-related differences in proliferative response of cardiac fibroblasts to hypoxia: effects of estrogen.
Mol Cell Biochem
215:
21-30,
2000[Web of Science][Medline].
18.
Haghighi, K,
Schmidt AG,
Hoit BD,
Brittsan AG,
Yatani A,
Lester JW,
Zhai J,
Kimura Y,
Dorn GW, II,
MacLennan DH,
and
Kranias EG.
Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure.
J Biol Chem
276:
24145-24152,
2000.
19.
Hasenfuss, G.
Alterations of calcium-regulatory proteins in heart failure.
Cardiovasc Res
37:
279-289,
1998
20.
Hasenfuss, G,
Reinecke H,
Studer R,
Meyer M,
Pieske B,
Holtz J,
Holubarsch C,
Posival H,
Just H,
and
Drexler H.
Relationship between myocardial function and expression of sarcoplasmic reticulum Ca2+-ATPase in failing and nonfailing human myocardium.
Circ Res
75:
434-442,
1994
21.
Hobai, IA,
and
O'Rourke B.
Decreased sarcoplasmic reticulum calcium content is responsible for defective excitation-contraction coupling in canine heart failure.
Circulation
103:
1577-1584,
2001.
22.
Houser, SR,
and
Lakatta EG.
Function of the cardiac myocyte in the conundrum of end-stage, dilated human heart failure.
Circulation
99:
600-604,
1999.
23.
Kadokami, T,
Frye C,
Lemster B,
Wagner CL,
Feldman AM,
and
McTiernan CF.
Anti-TNF-
antibody limits heart failure in a transgenic model.
Circulation
104:
1094-1097,
2001.
24.
Kadokami, T,
McTiernan CF,
Kubota T,
Frye CS,
and
Feldman AM.
Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF receptor expression.
J Clin Invest
106:
589-597,
2000[Web of Science][Medline].
25.
Komuro, I,
and
Yazaki Y.
Control of cardiac gene expression by mechanical stress.
Annu Rev Physiol
55:
55-75,
1993.
26.
Krown, KA,
Yasui K,
Brooker MJ,
Dubin AE,
Nguyen C,
Harris GL,
McDonough PM,
Glembotski CC,
Palade PT,
and
Sabbadini RA.
TNF
receptor expression in rat cardiac myocytes: TNF
inhibition of L-type Ca2+ current and Ca2+ transients.
FEBS Lett
376:
24-30,
1995[Web of Science][Medline].
27.
Kruger, C,
Erdmann E,
Nabauer M,
and
Beuckelmann DJ.
Intracellular calcium handling in isolated ventricular myocytes from cardiomyopathic hamsters (strain BIO 14.6) with congestive heart failure.
Cell Calcium
16:
500-508,
1994[Web of Science][Medline].
28.
Kubota, T,
Bounoutas GS,
Miyagishima M,
Kadokami T,
Sanders VJ,
Bruton C,
Robbins PD,
McTiernan CF,
and
Feldman AM.
Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy.
Circulation
101:
2518-2525,
2000.
29.
Kubota, T,
McTiernan CF,
Frye CS,
Slawson SE,
Lemster BH,
Koretsky AP,
Demetris AJ,
and
Feldman AM.
Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-
.
Circ Res
81:
627-635,
1997
30.
Leri, A,
Malhotra A,
Liew CC,
Kajstura J,
and
Anversa P.
Telomerase activity in rat cardiac myocytes is age and gender dependent.
J Mol Cell Cardiol
32:
385-390,
2000[Web of Science][Medline].
31.
Li, YY,
Feng YQ,
Kadokami T,
McTiernan CF,
Draviam R,
Watkins SC,
and
Feldman AM.
Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor
can be modulated by anti-tumor necrosis factor
therapy.
Proc Natl Acad Sci USA
97:
12746-12751,
2000
32.
Li, YY,
McTiernan CF,
and
Feldman AM.
Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling.
Cardiovasc Res
46:
214-224,
2000
33.
Linck, B,
Boknik P,
Eschenhagen T,
Muller FU,
Neumann J,
Nose M,
Jones LR,
Schmitz W,
and
Scholz H.
Messenger RNA expression and immunological quantification of phospholamban and SR-Ca2+-ATPase in failing and nonfailing human hearts.
Cardiovasc Res
31:
625-632,
1996[Web of Science][Medline].
34.
Litwin, SE,
and
Bridge JH.
Enhanced Na+-Ca2+ exchange in the infracted heart. Implications for excitation-contraction coupling.
Circ Res
81:
1083-1093,
1997
35.
Lompre, AM,
Schwartz K,
d'Albis A,
Lacombe G,
Theim NV,
and
Swyaghedauw B.
Myosin isoenzyme redistribution in chronic heart overload.
Nature
282:
105-107,
1979[Medline].
36.
Magid, NR,
Borer JS,
Young MS,
Wallerson DC,
and
DeMonteiro C.
Suppression of protein degradation in progressive cardiac hypertrophy of chronic aortic regurgitation.
Circulation
87:
1249-1257,
1993.
37.
Malhotra, A,
Buttrick P,
and
Scheuer J.
Effects of sex hormones on development of physiological and pathological cardiac hypertrophy in male and female rats.
Am J Physiol Heart Circ Physiol
259:
H866-H871,
1990
38.
Mann, DL.
Mechanisms and models in heart failure. A combinatory approach.
Circulation
100:
999-1008,
1999.
39.
Marx, SO,
Reiken S,
Hisamatsu Y,
Jayaraman T,
Burkhoff D,
Rosemblit N,
and
Marks AR.
PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts.
Cell
101:
365-376,
2000[Web of Science][Medline].
40.
McCall, E,
Ginsburg KS,
Bassani RA,
Shannon TR,
Qi M,
Samarel AM,
and
Bers DM.
Ca flux, contractility, and excitation-contraction coupling in hypertrophied rat ventricular myocytes.
Am J Physiol Heart Circ Physiol
274:
H1348-H1360,
1998
41.
McTiernan, CF,
Lemster BH,
Frye CS,
Combes A,
and
Feldman AM.
Interleukin-1
inhibits phospholamban gene expression in cultured cardiomyocytes.
Circ Res
81:
493-503,
1997
42.
Mercadier, JJ,
Lompre AM,
Duc P,
Boheler KR,
Fraysse JB,
Wisnewsky C,
Allen PD,
Komajda M,
and
Schwartz K.
Altered sarcoplasmic reticulum Ca2+-ATPase gene expression in the human ventricle during end-stage heart failure.
J Clin Invest
85:
305-309,
1990[Web of Science][Medline].
43.
Meyer, M,
Schillinger W,
Pieske B,
Holubarsch C,
Heilmann C,
Posival H,
Kuwajima G,
Mikoshiba K,
Just H,
and
Hasenfuss G.
Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy.
Circulation
92:
778-784,
1995.
44.
Movsesian, MA,
Karimi M,
Green K,
and
Jones LR.
Molecular and cellular responses: Ca2+-transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium.
Circulation
90:
653-657,
1994.
45.
Movsesian, MA,
and
Schwinger RHG
Calcium sequestration by the sarcoplasmic reticulum in heart failure.
Cardiovasc Res
37:
352-359,
1998
46.
Nagai, R,
Zarain-Herzberg A,
Brandl CJ,
Fujii T,
Tada M,
McLennan DH,
Alpert NR,
and
Periasamy M.
Regulation of myocardial Ca2+-ATPase and phospholamban mRNA expression in response to pressure overload and thyroid hormone.
Proc Natl Acad Sci USA
74:
555-564,
1994.
47.
Nakao, K,
Minobe W,
Roden R,
Bristow MR,
and
Leinwand LA.
Myosin heavy chain expression in human heart failure.
J Clin Invest
100:
2362-2370,
1997[Web of Science][Medline].
48.
Netticadan, T,
Temsha RM,
Kawabata K,
and
Dhalla NS.
Sarcoplasmic reticulum Ca2+/calmodulin-dependent protein kinase is altered in heart failure.
Circ Res
86:
596-605,
2000
49.
Olsson, MC,
Palmer BM,
Leinwand LA,
and
Moore RL.
Gender and aging in a transgenic mouse model of hypertrophic cardiomyopathy.
Am J Physiol Heart Circ Physiol
280:
H1136-H1144,
2001
50.
Onodera, T,
Tamura T,
Said S,
McCune S,
and
Gerdes AM.
Maladaptive remodeling of cardiac myocytes shape begins long before failure in hypertension.
Hypertension
32:
753-757,
1998
51.
Schmidt, U,
Hajjar RJ,
Kim CS,
Lebeche D,
Doye AA,
and
Gwathmey JK.
Human heart failure: cAMP stimulation of SR Ca2+-ATPase activity and phosphorylation level of phospholamban.
Am J Physiol Heart Circ Physiol
277:
H474-H480,
1999
52.
Schwinger, RH,
Bohm M,
Schmidt U,
Karczewski P,
Bavendiek U,
Flesch M,
Krause EG,
and
Erdmann E.
Unchanged protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and SR Ca2+-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts.
Circulation
92:
3220-3228,
1995.
53.
Scheuer, J,
Malhotra A,
Schaible TF,
and
Capasso J.
Effects of gonadectomy and hormonal replacement on rat hearts.
Circ Res
61:
12-19,
1987
54.
Shorofsky, SR,
Aggarwal R,
Corretti M,
Baffa JM,
Strum JM,
Al-Seikhan BA,
Kobayashi YM,
Jones LR,
Wier WG,
and
Balke CW.
Cellular mechanisms of altered contractility in the hypertrophied heart. Big hearts, big sparks.
Circ Res
84:
424-434,
1999
55.
Sivasubramanian, N,
Coker ML,
Kurrelmeyer KM,
MacLellan WR,
DeMayo FJ,
Spinale FG,
and
Mann DL.
Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor.
Circulation
104:
826-831,
2001.
56.
Weinberg, EO,
Thienelt CD,
Katz SE,
Bartunek J,
Tajima M,
Rohrbacj S,
Douglas P,
and
Lorell BH.
Gender differences in molecular remodeling in pressure overload hypertrophy.
J Am Coll Cardiol
34:
264-273,
1999
57.
Wier, WG,
Egan TM,
Lopez-Lopez JR,
and
Balke CW.
Local control of excitation-contraction coupling in rat heart cells.
J Physiol
474:
463-471,
1994
58.
Wolska, BM,
and
Solaro RJ.
Method for isolation of adult mouse cardiac myocytes for studies of contraction and microfluorimetry.
Am J Physiol Heart Circ Physiol
271:
H1250-H1255,
1996
59.
Xu, H,
Guo W,
and
Nerbonne J.
Four kinetically distinct depolarization activated K+ currents in adult mouse ventricular myocytes.
J Gen Physiol
113:
661-677,
1999
60.
Yokoyama, T,
Nakano M,
Bednarczyk JL,
McIntyre BW,
Entman M,
and
Mann DL.
Tumor necrosis factor-
provokes a hypertrophic growth response in adult cardiac myocytes.
Circulation
95:
1247-1252,
1999.
61.
Yokoyama, T,
Vaca L,
Rossen RD,
Durante W,
Hazarika P,
and
Mann DL.
Cellular basis for negative inotropic effects of tumor necrosis factor-
in the adult mammalian heart.
J Clin Invest
92:
2303-2312,
1993[Web of Science][Medline].
This article has been cited by other articles:
![]() |
J.-B. Shen, R. Shutt, M. Agosto, A. Pappano, and B. T. Liang Reversal of cardiac myocyte dysfunction as a unique mechanism of rescue by P2X4 receptors in cardiomyopathy Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H1089 - H1095. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Sanchis, M. Llovera, M. Ballester, and J. X. Comella An alternative view of apoptosis in heart development and disease Cardiovasc Res, February 1, 2008; 77(3): 448 - 451. [Full Text] [PDF] |
||||
![]() |
J.-B. Shen, R. Shutt, A. Pappano, and B. T. Liang Characterization and mechanism of P2X receptor-mediated increase in cardiac myocyte contractility Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3056 - H3062. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S. Petkova-Kirova, E. Gursoy, H. Mehdi, C. F. McTiernan, B. London, and G. Salama Electrical remodeling of cardiac myocytes from mice with heart failure due to the overexpression of tumor necrosis factor-{alpha} Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H2098 - H2107. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Saba, A. M. Janczewski, L. C. Baker, V. Shusterman, E. C. Gursoy, A. M. Feldman, G. Salama, C. F. McTiernan, and B. London Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-{alpha} Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1456 - H1467. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kawamura, T. Kubota, S. Kawano, Y. Monden, A. M. Feldman, H. Tsutsui, A. Takeshita, and K. Sunagawa Blockade of NF-{kappa}B improves cardiac function and survival without affecting inflammation in TNF-{alpha}-induced cardiomyopathy Cardiovasc Res, June 1, 2005; 66(3): 520 - 529. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ikeuchi, H. Tsutsui, T. Shiomi, H. Matsusaka, S. Matsushima, J. Wen, T. Kubota, and A. Takeshita Inhibition of TGF-{beta} signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction Cardiovasc Res, December 1, 2004; 64(3): 526 - 535. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ramani, M. Mathier, P. Wang, G. Gibson, S. Togel, J. Dawson, A. Bauer, S. Alber, S. C. Watkins, C. F. McTiernan, et al. Inhibition of tumor necrosis factor receptor-1-mediated pathways has beneficial effects in a murine model of postischemic remodeling Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1369 - H1377. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. P.M van Empel and L. J De Windt Myocyte hypertrophy and apoptosis: a balancing act Cardiovasc Res, August 15, 2004; 63(3): 487 - 499. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-J. Du Gender modulates cardiac phenotype development in genetically modified mice Cardiovasc Res, August 15, 2004; 63(3): 510 - 519. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. MacGowan, C. Evans, T. C.-C. Hu, D. Debrah, S. Mullet, H.-H. Chen, C. F. McTiernan, A. F.R. Stewart, A. P. Koretsky, and S. G. Shroff Troponin I protein kinase C phosphorylation sites and ventricular function Cardiovasc Res, August 1, 2004; 63(2): 245 - 255. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M Janczewski, M. Zahid, B. H Lemster, C. S Frye, G. Gibson, Y. Higuchi, E. G Kranias, A. M Feldman, and C. F McTiernan Phospholamban gene ablation improves calcium transients but not cardiac function in a heart failure model Cardiovasc Res, June 1, 2004; 62(3): 468 - 480. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Aravamudan, D. Volonte, R. Ramani, E. Gursoy, M. P. Lisanti, B. London, and F. Galbiati Transgenic overexpression of caveolin-3 in the heart induces a cardiomyopathic phenotype Hum. Mol. Genet., November 1, 2003; 12(21): 2777 - 2788. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |